HUTCHMED Ltd - HCM Net earnings per share for the last 12 months

Hutchison MediPharma (HCM) - corporate logo

Risks for HUTCHMED (China) Limited (HCM) are linked to potential clinical trial failures and delays in the US amid high cash burn. This is offset by a biopharmaceutical ecosystem featuring its own screening system and distribution network in the PRC. Global revenue is driven by patent royalties through partnerships with industry behemoths. The rolling YoY change in earnings per share illustrates a trend where -95.80 shows the level of this metric.

hutch-med.com (HCM): Earnings per share for the last twelve months from 02/11/2024 to 11/18/2026

HUTCHMED Corp - analytical breakdowns and key metrics (HCM)

- share price and consensus valuation forecast:
Fundamental valuation:HCM, HUTCHMED Ltd
Core merchandise of HUTCHMED Ltd

Developing innovative oncology drugs requires colossal expenditures, making the annual percentage growth chart of EPS TTM critically important for tracking the moment HUTCHMED (China) Limited (HCM) transitions to real profitability. This indicator measures the dynamics of net income per share over the last twelve months, allowing investors to objectively assess the pace of therapy monetization and the efficiency of capital management amid market volatility.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months